Clinical Trial: A Phase 2, Single-arm Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.

U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07660172) titled 'A Phase 2, Single-arm Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.' on June 15.

Brief Summary: The purpose of this study is to assess the efficacy, safety and pharmacokinetics (PK) of ianalumab (VAY736) in addition to eltrombopag treatment; and to inform the dose of ianalumab in pediatric patients (5 to <18 years of age) with primary ITP who have had an insufficient response to or relapsed after first-line treatment with corticosteroids.

Study Start Date: Feb. 08, 2027

Study Type: INTERVENTIONAL

Condition: Primary Immune Thrombocytopenia (ITP)

Intervention: BI...